Nigeria’s push to make more medicines at home is moving upstream, with health and industry stakeholders examining how the country can start producing the essential ingredients that give drugs their therapeutic effect.
From finished medicines to core ingredients
Nigeria Health Watch and the World Bank Group convened a special session in Abuja on Friday on domestic production of active pharmaceutical ingredients, or APIs. The discussion was set to identify one or two priority ingredients that Nigeria could realistically begin manufacturing, and the reforms needed to make production viable.
DGBN has also reported on Ghana welcomes Uganda Airlines as new Accra service links East and West Africa.
Nigeria already manufactures some finished medicines, but it remains heavily dependent on imported APIs. That reliance leaves local producers exposed to foreign-exchange pressures, price swings and international supply disruptions — costs that can reach patients through shortages or higher medicine prices.
The organisers said the agenda includes infrastructure, regulation and quality assurance, technology and skills, finance, investment and reliable demand. Those issues matter because making APIs requires a deeper industrial base than simply formulating finished medicines from imported inputs.
A health-security and economic question
The case for local API production is not only about industrial policy. It is also about whether families can obtain safe, affordable treatment when global markets are disrupted.
World Bank analysis estimates that roughly 70 per cent of pharmaceuticals consumed in Nigeria are imported, despite growth in domestic manufacturing. Its research says local output more than doubled between 2018 and 2024, while the number of pharmaceutical firms rose from 115 to 186. Yet the industry needs more dependable electricity, access to affordable finance and foreign exchange, quality upgrades and predictable purchasing arrangements to compete.
For more context, read DGBN’s coverage of Ghana and Egypt target deeper ties in defence, medicines and infrastructure.
For Black communities across Nigeria and West Africa, the stakes are immediate. Imported inputs priced in foreign currency can make essential medicines less affordable in a country where many households pay directly for care. A more resilient local supply chain could also support skilled manufacturing jobs and give Nigeria a stronger role in regional health production.
Policies need to become production
Nigeria’s health compact sets out measures intended to support local manufacturing, including identifying APIs linked to essential medicines, streamlining certification, using procurement and reimbursement systems to support supply security, and developing API parks with reliable power, waste treatment and logistics.
The government has also placed localisation at the centre of its Presidential Initiative for Unlocking the Healthcare Value Chain. But the critical test is whether policy incentives translate into factories that can meet strict quality standards and sell consistently into a sufficiently large market.
The World Bank and African Union’s AIM2030 initiative identifies Nigeria as one of the countries targeted for expanded African manufacturing of essential health products. Its approach combines infrastructure and skills investments with stronger regulation, regional market coordination and private-sector finance.
What happens next
The Abuja session does not itself establish an API plant. Instead, it is designed to narrow the gap between broad commitments and a practical starting point: which priority APIs to make, who will invest, how quality will be assured and how manufacturers will be guaranteed demand.
Related DGBN reporting includes Antigua and Barbuda Seeks AI and Expanded PAHO Support to Reinforce Healthcare.
That focus is significant. Local API production is a long-term undertaking, but selecting feasible first products and creating a credible investment environment could help Nigeria reduce its vulnerability to imported medicine inputs while building a stronger pharmaceutical base for the region.